Metaplastic Breast Cancer: Current Understanding and Future Directions.

[1]  A. Vincent-Salomon,et al.  TROP2, androgen receptor, and PD‐L1 status in histological subtypes of high‐grade metaplastic breast carcinomas , 2022, Histopathology.

[2]  K. Kalinsky,et al.  Trop-2 as a Therapeutic Target in Breast Cancer , 2022, Cancers.

[3]  Yuan Guo,et al.  Nomogram for the prediction of triple-negative breast cancer histological heterogeneity based on multiparameter MRI features: A preliminary study including metaplastic carcinoma and non- metaplastic carcinoma , 2022, Frontiers in Oncology.

[4]  Yanni Jiang,et al.  Metaplastic Carcinoma of the Breast: MRI Features with Clinical and Histopathologic Correlation. , 2022, Academic radiology.

[5]  R. Verma,et al.  Clinicopathologic Features of Metaplastic Breast Carcinoma: Experience From a Tertiary Cancer Center of North India , 2022, Cureus.

[6]  S. Bandyopadhyay,et al.  Estrogen receptor status has no prognostic relevance in metaplastic breast carcinoma , 2022, Cancer treatment and research communications.

[7]  L. Testa,et al.  Disease Behavior and Treatment Response of Special Histological Types of Triple-Negative Breast Cancer. , 2022, Clinical breast cancer.

[8]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[9]  Jeffrey T. Chang,et al.  Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  M. Dooms,et al.  Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders , 2022, Frontiers in Pharmacology.

[11]  G. Wang,et al.  Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma. , 2022, Annals of diagnostic pathology.

[12]  E. B. Butler,et al.  Neoadjuvant Chemotherapy for Metaplastic Breast Cancer: Response Rates, Management, and Outcomes. , 2022, Clinical breast cancer.

[13]  C. Perou,et al.  Molecular analysis of TCGA breast cancer histologic types , 2021, Cell genomics.

[14]  R. Gray,et al.  A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609) , 2021, Clinical Cancer Research.

[15]  G. Plitas,et al.  Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma , 2021, NPJ breast cancer.

[16]  S. Ganesan,et al.  Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer , 2021, Case Reports in Oncology.

[17]  J. Reis-Filho,et al.  PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays , 2021, The American journal of surgical pathology.

[18]  C. Criscitiello,et al.  Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review , 2021, Breast Cancer Research and Treatment.

[19]  M. Piccart,et al.  Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. , 2021, The New England journal of medicine.

[20]  Z. Nahleh,et al.  Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US , 2021, JAMA network open.

[21]  G. Plitas,et al.  Survival Outcomes for Metaplastic Breast Cancer Differ by Histologic Subtype , 2021, Annals of Surgical Oncology.

[22]  N. Meropol,et al.  Bridging the divide between clinical research and clinical care in oncology: An integrated real-world evidence generation platform , 2021, Digital health.

[23]  H. Abdel-Razeq,et al.  Metaplastic Breast Carcinoma: Experience of a Tertiary Cancer Center in the Middle East , 2021, Cancer control : journal of the Moffitt Cancer Center.

[24]  J. Cameselle-Teijeiro,et al.  New criteria to select patients with breast cancer to perform germline BRCA1/2 testing , 2021, Clinical Obstetrics, Gynecology and Reproductive Medicine.

[25]  I. Chen,et al.  Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components , 2020, Virchows Archiv.

[26]  J. Reis-Filho,et al.  The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas , 2020, Molecular oncology.

[27]  P. Kuo,et al.  Big Data Solutions for Controversies in Breast Cancer Treatment. , 2020, Clinical breast cancer.

[28]  J. Pérez-García,et al.  Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma , 2020, Cancers.

[29]  S. Gallus,et al.  Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis , 2020, BMC Cancer.

[30]  Masayuki Yoshida,et al.  Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation , 2020, Case reports in oncological medicine.

[31]  G. Babiera,et al.  Outcomes after Treatment of Metaplastic Versus Other Breast Cancer Subtypes , 2020, Journal of Cancer.

[32]  K. Hess,et al.  Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Al-Tweigeri,et al.  Complete Response of Chemo-Refractory Metastatic Metaplastic Breast Cancer to Paclitaxel-Immunotherapy Combination , 2019, The American journal of case reports.

[34]  G. Calin,et al.  The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database , 2019, Journal of Translational Medicine.

[35]  Yukako Yagi,et al.  Implementation of Digital Pathology Offers Clinical and Operational Increase in Efficiency and Cost Savings. , 2019, Archives of pathology & laboratory medicine.

[36]  E. Romond,et al.  Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution. , 2019, Clinical breast cancer.

[37]  D. Visscher,et al.  Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy , 2019, Breast cancer research and treatment.

[38]  M. Gurcan,et al.  Digital pathology and artificial intelligence. , 2019, The Lancet. Oncology.

[39]  E. Lee,et al.  Different Patterns of Conditional Survival of Breast Cancer Patients by Age and Histologic Types: Evidence from the Korean Nationwide Registry , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[40]  M. Beg,et al.  Survival and treatment outcomes of metaplastic breast carcinoma: Single tertiary care center experience in Pakistan. , 2019, Indian journal of cancer.

[41]  P. Arasteh,et al.  Does metaplastic breast carcinoma demonstrate a different clinicopathological behavior in our region: The Shiraz Breast Cancer Registry , 2019, The breast journal.

[42]  I. Chen,et al.  PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[43]  M. Gurcan,et al.  Relationship between the Ki67 index and its area based approximation in breast cancer , 2018, BMC Cancer.

[44]  S. Hoover,et al.  Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis. , 2018, European journal of cancer.

[45]  Jubilee Brown,et al.  Clinical trial methodology in rare gynecologic tumor research: Strategies for success. , 2018, Gynecologic oncology.

[46]  T. Hyslop,et al.  Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database , 2018, Annals of Surgical Oncology.

[47]  Berkman Sahiner,et al.  Optimized generation of high-resolution phantom images using cGAN: Application to quantification of Ki67 breast cancer images , 2018, PloS one.

[48]  L. Miller,et al.  Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014. , 2018, The oncologist.

[49]  C. Maher,et al.  Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast , 2017, npj Breast Cancer.

[50]  A. Jemal,et al.  The burden of rare cancers in the United States , 2017, CA: a cancer journal for clinicians.

[51]  K. Hess,et al.  Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab , 2017, JAMA oncology.

[52]  O. Mariani,et al.  The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas , 2017, Clinical Cancer Research.

[53]  O. Elemento,et al.  Role of RPL39 in Metaplastic Breast Cancer , 2017, Journal of the National Cancer Institute.

[54]  Congmin Liu,et al.  Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma , 2016, Oncotarget.

[55]  J. Palazzo,et al.  Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1 , 2016, Journal of Clinical Pathology.

[56]  E. Rakha,et al.  Imaging overview of metaplastic carcinomas of the breast: a large study of 71 cases. , 2016, The British journal of radiology.

[57]  P. Argani,et al.  A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma. , 2016, American journal of clinical pathology.

[58]  Guangliang Yin,et al.  Whole exome sequencing of rare aggressive breast cancer histologies , 2016, Breast Cancer Research and Treatment.

[59]  J. Blay,et al.  The value of research collaborations and consortia in rare cancers. , 2016, The Lancet. Oncology.

[60]  O. Mariani,et al.  Metastatic breast carcinomas display genomic and transcriptomic heterogeneity , 2015, Modern Pathology.

[61]  F. Climent,et al.  Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study , 2014, British Journal of Cancer.

[62]  M. Coleman,et al.  Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  T. Koehler,et al.  Hormone Receptor Status Does Not Affect Prognosis in Metaplastic Breast Cancer: A Population-Based Analysis with Comparison to Infiltrating Ductal and Lobular Carcinomas , 2014, Annals of Surgical Oncology.

[64]  R. Nelson,et al.  Survival Outcomes of Metaplastic Breast Cancer Patients: Results from a US Population-based Analysis , 2014, Annals of Surgical Oncology.

[65]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[66]  Chiun-Sheng Huang,et al.  Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era , 2011, Breast Cancer Research and Treatment.

[67]  Metin Nafi Gürcan,et al.  Computerized classification of intraductal breast lesions using histopathological images , 2011, IEEE Transactions on Biomedical Engineering.

[68]  A. Luini,et al.  Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature , 2007, Breast Cancer Research and Treatment.

[69]  K. Bland,et al.  Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data Base , 2006, Annals of Surgical Oncology.

[70]  S. Lakhani,et al.  Metaplastic breast carcinomas are basal‐like tumours , 2006, Histopathology.

[71]  G. Hortobagyi,et al.  Biphasic metaplastic sarcomatoid carcinoma of the breast. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  Berkman Sahiner,et al.  Optimal neural network architecture selection: improvement in computerized detection of microcalcifications. , 2002, Academic radiology.

[73]  Berkman Sahiner,et al.  Computer-aided characterization of mammographic masses: accuracy of mass segmentation and its effects on characterization , 2001, IEEE Transactions on Medical Imaging.